Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/12655
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMakarasen A.
dc.contributor.authorKuno M.
dc.contributor.authorPatnin S.
dc.contributor.authorReukngam N.
dc.contributor.authorKhlaychan P.
dc.contributor.authorDeeyohe S.
dc.contributor.authorIntachote P.
dc.contributor.authorSaimanee B.
dc.contributor.authorSengsai S.
dc.contributor.authorBoonsri P.
dc.contributor.authorChaivisuthangkura A.
dc.contributor.authorSirithana W.
dc.contributor.authorTechasakul S.
dc.contributor.authorDr.
dc.date.accessioned2021-04-05T03:04:46Z-
dc.date.available2021-04-05T03:04:46Z-
dc.date.issued2019
dc.identifier.issn21949379
dc.identifier.other2-s2.0-85075814506
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/12655-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075814506&doi=10.1055%2fa-0968-1150&partnerID=40&md5=ff3b3822d05ec10d157aa7796904d722
dc.description.abstractIn this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 μM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC 50 of 4.63±0.62 μg/mL, which was similar with that in EFV and TMC278 (IC 50 7.76±0.37 and 1.57±0.20 μg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. © 2019 Georg Thieme Verlag. All rights reserved.
dc.subject4 (2',6' dimethyl 4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject4 (2',6' dimethyl 4' cyanophenoxy) 2 chloroquinoline
dc.subject4 (2',6' dimethyl 4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject4 (2',6' dimethyl 4' cyanophenoxy) 6 nitroquinoline
dc.subject4 (2',6' dimethyl 4' formylphenoxy) 2 (4'' cyanophenyl)aminoquinoline
dc.subject4 (2',6' dimethyl 4' formylphenoxy) 2 chloroquinoline
dc.subject4 (2',6' dimethyl 4' formylphenoxy) 6 (4" cyanophenyl)aminoquinoline
dc.subject4 (2',6' dimethyl 4' formylphenoxy) 6 nitroquinoline
dc.subject4 (4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject4 (4' cyanophenoxy) 2 chloroquinoline
dc.subject4 (4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject4 (4' cyanophenoxy) 6 nitroquinoline
dc.subject4 (4' formylphenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject4 (4' formylphenoxy) 2 chloroquinoline
dc.subject4 (4' formylphenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject4 (4' formylphenoxy) 6 nitroquinoline
dc.subjectanti human immunodeficiency virus agent
dc.subjectantileukemic agent
dc.subjectdoxorubicin
dc.subjectefavirenz
dc.subjectetoposide
dc.subjectetravirine
dc.subjectnevirapine
dc.subjectnonnucleoside reverse transcriptase inhibitor
dc.subjectquinoline derivative
dc.subjectrilpivirine
dc.subjectunclassified drug
dc.subjectanti human immunodeficiency virus agent
dc.subjectbenzoxazine derivative
dc.subjectefavirenz
dc.subjectetravirine
dc.subjectnevirapine
dc.subjectpyridazine derivative
dc.subjectquinoline derivative
dc.subjectreverse transcriptase, Human immunodeficiency virus 1
dc.subjectrilpivirine
dc.subjectRNA directed DNA polymerase
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectantileukemic activity
dc.subjectantiviral activity
dc.subjectArticle
dc.subjectcell viability
dc.subjectcomparative study
dc.subjectconcentration response
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectdrug conformation
dc.subjectdrug cytotoxicity
dc.subjectdrug design
dc.subjectdrug potency
dc.subjectdrug protein binding
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjectenzyme inhibition
dc.subjectenzyme linked immunosorbent assay
dc.subjecthuman
dc.subjecthuman cell
dc.subjectHuman immunodeficiency virus 1
dc.subjecthydrogen bond
dc.subjectIC50
dc.subjectmolecular docking
dc.subjectmolecular hybridization
dc.subjectMOLT-3 cell line
dc.subjectMRC-5 cell line
dc.subjectMTT assay
dc.subjectpharmacophore
dc.subjectstructure activity relation
dc.subjectXTT assay
dc.subjectchemistry
dc.subjectdrug effect
dc.subjectHuman immunodeficiency virus 1
dc.subjectHuman immunodeficiency virus infection
dc.subjectmetabolism
dc.subjectmolecular docking
dc.subjecttumor cell line
dc.subjectAnti-HIV Agents
dc.subjectBenzoxazines
dc.subjectCell Line, Tumor
dc.subjectDiarylquinolines
dc.subjectHIV Infections
dc.subjectHIV Reverse Transcriptase
dc.subjectHIV-1
dc.subjectHumans
dc.subjectMolecular Docking Simulation
dc.subjectNevirapine
dc.subjectPyridazines
dc.subjectReverse Transcriptase Inhibitors
dc.subjectRilpivirine
dc.titleMolecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationDrug Research. Vol 69, No.12 (2019), p.671-682
dc.identifier.doi10.1055/a-0968-1150
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.